Home/Pipeline/ADCT-601

ADCT-601

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

ADC Therapeutics

About ADC Therapeutics

ADC Therapeutics is a commercial-stage oncology company with a mission to transform cancer treatment through its proprietary ADC platform. Its key achievement is the FDA approval and commercialization of ZYNLONTA® for relapsed/refractory large B-cell lymphoma, establishing a revenue base. The company's strategy is to maximize ZYNLONTA's potential through label expansion while leveraging its differentiated linker/payload technology to advance a focused pipeline in high-need oncology indications.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
NST-101 (estimated)	Novastage Pharmaceuticals	Phase 1/2	Active
Meta10-TILs	Leman Biotech	Phase 1	Active (Investigator-Initiated Trial)
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
P-002	Panacea Biotec	Phase 1/2	Active
Undisclosed kinase inhibitor	Tyligand Bioscience	Phase 1	Active
TYK-001	TYK Medicines	Phase 1/2	Active
PT-112	SciClone Pharmaceuticals	Phase 1	Active - Subject Recruitment
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion